Clinical Research Directory

Participant: Inclusion Criteria: * confirmed HD mutation carriers and/or established family history alongside typical symptoms (i.e. chorea) of HD; * early (stages 1 and 2) or moderate (stage 3) stages according to Shoulson-Fahn * exhibit mild to moderate behavioral symptoms defined by severity scores in the PBA-S between 1 and 3 for any of the evaluated symptoms and no symptoms with a severity score of 4 * stable doses of medications for at least one month * Have a caregiver willing to be present during tDCS sessions and answer questionnaires. Exclusion Criteria: * unstable medical conditions * history of epilepsy * metallic objects in the brain * Have a caregiver willing to be present during tDCS sessions and answer questionnaires. * clinical diagnosis of major cognitive disorder or dementia * Have risk of suicidal behavior, defined as any suicidal behavior or suicidal ideation of type 4 or type 5 based on the Columbia-Suicide Severity Rating Scale (C-SSRS) in the 3 months prior to screening * simultaneous participation in other clinical trial * Individuals determined to be incapable of consent per past medical history or via assessment by the study staff at time of consent. Caregiver: Inclusion Criteria: -willingness to participate in the study Exclusion Criteria: -motor/cognitive symptoms related to Alzheimer's disease or Huntington's disease that might impair the ability to assist the participant during the research study.